Glaukos Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last year. There are currently 2 sell ratings and 6 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Glaukos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GKOS, but not buy additional shares or sell existing shares.
View analyst ratings for Glaukos or view top-rated stocks.

Wall Street analysts have given Glaukos a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Glaukos wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Glaukos is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Glaukos.

Glaukos will be holding an earnings conference call on Thursday, August 5th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Glaukos Co. (NYSE:GKOS) announced its quarterly earnings results on Wednesday, May, 5th. The medical instruments supplier reported ($0.21) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.30) by $0.09. The medical instruments supplier had revenue of $67.97 million for the quarter, compared to analysts' expectations of $64.82 million. Glaukos had a negative trailing twelve-month return on equity of 6.44% and a negative net margin of 34.83%.
View Glaukos' earnings history.

Glaukos' stock was trading at $38.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, GKOS stock has increased by 32.0% and is now trading at $51.00.
View which stocks have been most impacted by COVID-19.

Glaukos issued an update on its second quarter 2021 earnings guidance on Wednesday, May, 26th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $70 million-$72 million, compared to the consensus revenue estimate of $69.56 million.

8 Wall Street analysts have issued 12 month price targets for Glaukos' shares. Their forecasts range from $34.00 to $105.00. On average, they anticipate Glaukos' stock price to reach $63.00 in the next year. This suggests a possible upside of 23.5% from the stock's current price.
View analysts' price targets for Glaukos or view top-rated stocks among Wall Street analysts.

10 employees have rated Glaukos CEO Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among Glaukos' employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Glaukos include Hill-Rom (HRC), Globus Medical (GMED), Tandem Diabetes Care (TNDM), ShockWave Medical (SWAV), Integra LifeSciences (IART), Nevro (NVRO), Inspire Medical Systems (INSP), Inari Medical (NARI), ICU Medical (ICUI), AtriCure (ATRC), Merit Medical Systems (MMSI), NuVasive (NUVA), Haemonetics (HAE), Axonics (AXNX) and The Beauty Health (SKIN).
View all of GKOS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and The Boeing (BA).

(GKOS) raised $76 million in an initial public offering on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

Glaukos' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Alliancebernstein L.P. (0.15%), Taylor Frigon Capital Management LLC (0.15%) and State of Alaska Department of Revenue (0.07%). Company insiders that own Glaukos stock include Joseph E Gilliam, Thomas William Burns and William J Phd Link.
View institutional ownership trends for Glaukos.

GKOS stock was sold by a variety of institutional investors in the last quarter, including Taylor Frigon Capital Management LLC. Company insiders that have sold Glaukos company stock in the last year include Joseph E Gilliam, and William J Phd Link.
View insider buying and selling activity for Glaukos or view top insider-selling stocks.

GKOS stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., and State of Alaska Department of Revenue.
View insider buying and selling activity for Glaukos or or view top insider-buying stocks.

Shares of GKOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GKOS stock can currently be purchased for approximately $51.00.

Glaukos has a market capitalization of $2.36 billion and generates $224.96 million in revenue each year. The medical instruments supplier earns $-120,350,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.

Glaukos employs 653 workers across the globe.

The official website for Glaukos is www.glaukos.com.

Glaukos is headquartered at 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672.

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The medical instruments supplier can be reached via phone at 949-367-9600 or via email at [email protected]